Amylyx Pharmaceuticals (NASDAQ:AMLX) Issues Quarterly Earnings Results, Meets Expectations

Amylyx Pharmaceuticals (NASDAQ:AMLX) released its quarterly earnings results on Thursday. The company reported ($0.38) earnings per share for the quarter, hitting the consensus estimate of ($0.38), FiscalAI reports.

Here are the key takeaways from Amylyx Pharmaceuticals’ conference call:

• Avexitide’s Phase III LUCIDITY trial met its primary and all secondary endpoints, including a 55% reduction in the composite rate of level 2 and level 3 hypoglycemic events versus placebo, with a favorable safety profile. Amylyx remains on track to submit an NDA by year-end and is preparing for a potential 2027 launch, subject to FDA review.
• An oversubscribed equity offering generated $545 million in net proceeds, bringing cash and cash equivalents to $768 million at quarter-end. Management said the funds support NDA preparation, launch readiness, and pipeline development.
• The company estimates about 160,000 people in the U.S. live with PBH and reports growing physician interest in treatment options; a PBH-specific ICD-10 code took effect in October. These market-size and demand assessments are based on Amylyx’s analyses and research.
• Operating expenses rose 38% year over year to $49.7 million, reflecting higher trial spending and pre-commercialization costs; stock-based compensation also increased. The higher spending comes as Amylyx scales its commercial organization ahead of a possible launch.
• Beyond avexitide, Amylyx is targeting a 2027 IND filing for AMX0318, while its AMX0114 ALS trial has advanced to enrollment in its fourth dose cohort. The company also reported progress on a research collaboration, but did not provide new efficacy results for these programs.

Amylyx Pharmaceuticals Stock Down 6.1%

Shares of AMLX stock traded down $1.78 during trading hours on Thursday, hitting $27.62. The company’s stock had a trading volume of 2,210,040 shares, compared to its average volume of 1,297,574. Amylyx Pharmaceuticals has a twelve month low of $10.83 and a twelve month high of $41.14. The business has a fifty day moving average of $30.15 and a 200-day moving average of $20.35.

Insider Activity

In other Amylyx Pharmaceuticals news, insider Camille Bedrosian sold 10,028 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $32.40, for a total transaction of $324,907.20. Following the transaction, the insider owned 278,064 shares of the company’s stock, valued at $9,009,273.60. This represents a 3.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Gina Mazzariello sold 9,536 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $32.46, for a total transaction of $309,538.56. Following the completion of the sale, the insider directly owned 190,838 shares in the company, valued at $6,194,601.48. This represents a 4.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 60,374 shares of company stock valued at $1,815,257 over the last quarter. Insiders own 10.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on AMLX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Tuesday. Mizuho lifted their price objective on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, August 18th. Guggenheim lifted their price objective on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. Wolfe Research upgraded shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 17th. Finally, HC Wainwright increased their price target on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.14.

About Amylyx Pharmaceuticals